Immupharma PLC 2021 RESULT OF ANNUAL GENERAL MEETING (3228D)
June 28 2021 - 6:03AM
UK Regulatory
TIDMIMM
RNS Number : 3228D
Immupharma PLC
28 June 2021
28 June 2021
ImmuPharma PLC
("ImmuPharma" or the "Company")
2021 RESULT OF ANNUAL GENERAL MEETING - ALL RESOLUTIONS
PASSED
ImmuPharma PLC (LSE:IMM | Euronext Growth Brussels: ALIMM), the
specialist drug discovery and development company, held its AGM
earlier today, in accordance with COVID-19 guidance. The Company is
pleased to announce that all resolutions were duly passed.
The results of each resolution were as follows:
Resolution For % For Against % Against Withheld
1. To receive the accounts
of the Company for the
year ended 31 December
2020 together with the
reports thereon of the
directors and auditors
of the Company 27,979,197 99.93 20,000 0.07 663,319
----------- ------ ---------- ---------- ---------
2. To re-appoint Dr Stephane
Mery as a director of
the Company 22,040,754 76.93 6,610,683 23.07 11,079
----------- ------ ---------- ---------- ---------
3. To re-appoint Nexia
Smith & Williams as auditors
of the Company 28,003,061 99.92 22,348 0.08 637,107
----------- ------ ---------- ---------- ---------
4. That the directors
be authorised to allot
shares on the basis set
out in the Notice of Meeting 27,762,710 99.82 48,844 0.18 850,962
----------- ------ ---------- ---------- ---------
5. To waive pre-emption
rights in respect of the
issue of the shares on
the basis set out in the
Notice of Meeting 27,759,210 99.81 52,344 0.19 850,962
----------- ------ ---------- ---------- ---------
As at the date of the AGM, the number of issued ordinary shares
of the Company was 250,221,2975 shares, which was the total number
of shares entitling the holders to attend and vote for or against
all resolutions. In accordance with the Company's Articles of
Association, every member has one vote for every share held. Votes
withheld are not votes in law and have not been counted in the
calculation of the proportion of vote "for" or "against" a
resolution. Proxy appointments which gave discretion to the
Chairman have been included in the "for" total.
End
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases, metabolic diseases,
anti-infectives and cancer. The lead program, Lupuzor(TM), is a
first-in class autophagy immunomodulator which is in Phase 3 for
the treatment of lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals
signed on 28 November 2019, an exclusive licence and development
agreement and trademark agreement for Lupuzor(TM) to fund a new
international Phase 3 trial for Lupuzor(TM) and commercialise in
the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGDKFBKKBKDBAB
(END) Dow Jones Newswires
June 28, 2021 06:03 ET (10:03 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Oct 2023 to Oct 2024